Targeting regulated cell death pathways in acute myeloid leukemia

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Venetoclax, a BCL2 inhibitor, has improved outcomes for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy by inducing apoptosis.
• Despite venetoclax's efficacy, most patients eventually relapse, highlighting the need for alternative therapeutic strategies.
• Understanding molecular cell death pathways is crucial for translating basic science into clinical applications for AML.

Purpose of the Study:

• To review advances in targeting regulated cell death pathways beyond apoptosis in AML.
• To explore therapeutic opportunities for inducing regulated cell death in AML.
• To identify drug discovery challenges and clinical trial translation for novel cell death inducers in AML.

Main Methods:

• Comprehensive review of recognized regulated cell death pathways: apoptosis, necroptosis, ferroptosis, and autophagy.
• Analysis of therapeutic strategies to trigger regulated cell death in AML.
• Discussion of drug discovery challenges and clinical translation of new inducers.

Main Results:

• Venetoclax effectively targets intrinsic apoptosis in AML but acquired resistance necessitates exploring other cell death mechanisms.
• Multiple regulated cell death pathways (necroptosis, ferroptosis, autophagy) present therapeutic opportunities in AML.
• Developing novel inducers for these pathways faces significant drug discovery and clinical trial hurdles.

Conclusions:

• Targeting diverse regulated cell death pathways is a promising strategy to overcome venetoclax resistance in AML.
• Further research into molecular cell death mechanisms can lead to new therapies for refractory or resistant AML.
• Addressing drug discovery challenges is key to translating these findings into effective clinical treatments for AML patients.